看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
8 d; D* W' J$ N' n/ ^$ q
! x5 ]7 n2 l% X. h& f6 s9 D0 y& q; H# x# Y1 p" J7 v8 @
Currently available feasibility data for possible combination strategies.
% Y+ c$ N5 P8 T& P1 x————————————————————————————————0 d' o& R( G j1 M( G) ]/ F: ?
Combination Feasibility according to preliminary data . T7 C, t2 L, n
——————————————————————————————————
! t0 |/ w. g" C8 L+ E5 FBevacizumab + sorafenib Yes, reduced dose 0 f |5 G9 L" f4 ? t
Bevacizumab + sunitinib† No ) l' a: P! u7 ~
Bevacizumab + temsirolimus Yes
1 P8 r0 |, r9 I3 S! k. M, `* a5 Y) _5 wBevacizumab + everolimus Yes
" u# d! F* Z: D3 {& s9 ]+ QSorafenib + sunitinib ?
+ j, r9 M7 e& Q2 ySorafenib + temsirolimus Yes, reduced dose - a2 T1 R- B: ^$ ^0 h, P, M7 z
Sorafenib + everolimus Yes, reduced dose
' M' J- e8 d+ l* h+ KSunitinib + temsirolimus† No , O4 ?5 m0 n% C' q
Sunitinib + everolimus ?
1 B) h0 Q+ |$ nTemsirolimus + everolimus ?
0 [2 z+ x1 L; T: Q: w————————————————————
$ u* h) }) Z4 E& q3 z1 i†Led to US FDA warning.) y, v* |. L: A! Q
?: As yet unattempted combination.1 H/ g+ }/ q |0 i' t; W* m! ^
|